Influence of Formulation and Preparation Process on Ambroxol Hydrochloride Dry Powder Inhalation Characteristics and Aerosolization Properties

REFERENCES

• J. D. Andya, Y. Maa, H. R. Costantino, P. Nguyen, N. Dasovich, T. D. Sweeney, C. C. Hsu, and S. J. Shire. (1999). The effect of formulation expients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclinal antibody. Pharm. Res. 16:350–358.
   PubMed Web of Science ®Google Scholar
• P. J. Atkins. (2005). Dry powder inhalers: An overview. Respir. Care 50:1304–1312.
   PubMedGoogle Scholar
• C. Bosquillon, V. Préat, and R. Vanbever. (2004). Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J. Control. Release 96:233–244.
   PubMed Web of Science ®Google Scholar
• British Pharmacopoeia Commission. Density of solids: Bulk and tapped densityBritish pharmacopoeia. Her Majesty's Stationery Office Ltd, London, (2005), 4, A211–A212. Appendix VQ..
   Google Scholar
• M. J. Clarke, J. Peart, S. Cagnan, and P. R. Byron. (2002). Adhesion of powders for inhalation: An evaluation of drug detachment from surfaces following deposition from aerosol screams. Pharm. Res. 19:322–329.
   PubMed Web of Science ®Google Scholar
• V. Codrons, F. Vanderbist, B. Ucakar, V. Préat, and R. Vanbever. (2004). Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1–34) from rat lungs. J. Pharm. Sci. 93:1241–1252.
   PubMed Web of Science ®Google Scholar
• O. I. Corrigan. (1995). Thermal analysis of spray dried products. Thermochim. Acta 248:245–258.
   Web of Science ®Google Scholar
• D. O. Corrigan, O. I. Corrigan, and A. M. Healy. (2004). Predicting the physical state of spray dried composites: Salbutamol sulphate/lactose and salbutamol sulphate/polyethylene glycol co-spray dried systems. Int. J. Pharm. 273:171–182.
   PubMed Web of Science ®Google Scholar
• D. O. Corrigan, O. I. Corrigan, and A. M. Healy. (2006). Physical, chemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers. Int. J. Pharm. 322:22–30.
   PubMed Web of Science ®Google Scholar
• R. Dalby, and J. Suman. (2003). Inhalation therapy: Technological milestones in asthma treatment. Adv. Drug Deliv. Rev. 55:779–791.
   PubMed Web of Science ®Google Scholar
• B. G. Disse. (1987). The pharmacology of ambroxol––review and new results. Eur. J. Respir. Dis. Suppl. 153:255–262.
   PubMedGoogle Scholar
• D. L. French, D. A. Edwards, and R. W. Niven. (1996). The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J. Aerosol Sci. 27:769–783.
   Web of Science ®Google Scholar
• E. R. Geuns, J. S. Toren, D. M. Barends, and A. Bult. (1997). Decrease of the stage-2 deposition in the twin impinger during storage of beclomethasone dipropionate dry powder inhalers in controlled and uncontrolled humidities. Eur. J. Pharm. Biopharm. 44:187–194.
   Web of Science ®Google Scholar
• J. Glinski, G. Chavepeyer, and J. Platten. (2000). Surface properties of aqueous solutions of L-leucine. Biophys. Chem. 84:99–103.
   PubMed Web of Science ®Google Scholar
• A. J. Hickey, and N. M. Concessio. (1997). Descriptors of irregular particle morphology and powder properties. Adv. Drug Deliv. Rev. 26:29–40.
   PubMed Web of Science ®Google Scholar
• K. Ikegami, Y. Kawashima, H. Takeuchi, H. Yamamoto, K. Mimura, D. Momose, and K. Ouchi. (2003). A new agglomerated KSR-592 β-form crystal system for dry powder inhalation formulation to improve inhalation performance in vitro and in vivo. J. Control. Release 88:23–33.
   PubMed Web of Science ®Google Scholar
• M. Irngartinger, V. Camuglia, M. Damm, J. Goede, and H. W. Frijlink. (2004). Pulmonary delivery of therapeutic peptides via dry powder inhalation: Effects of micronisation and manufacturing. Eur. J. Pharm. Biopharm. 58:7–14.
   PubMed Web of Science ®Google Scholar
• H. Larhrb, G. P. Martin, C. Marriott, and D. Prime. (2003). The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int. J. Pharm. 257:283–296.
   PubMed Web of Science ®Google Scholar
• P. Lucas, K. Anderson, U. J. Potter, and J. N. Staniforth. (1999). Enhancement of small particle size dry powder aerosol formulations using an ultra low density additive. Pharm. Res. 16:1643–1647.
   PubMed Web of Science ®Google Scholar
• R. J. Malcolmson, and J. K. Embleton. (1998). Dry powder formulations for pulmonary delivery. Pharm. Sci. Technol. Today 1:394–398.
   Google Scholar
• A. R. Najafabadi, K. Gilani, M. Barghi, and M. Rafiee-Tehrani. (2004). The effect of vehicle on physical properties and aerosolization behavior of disodium cromoglycate microparticles spray dried alone or with L-leucine. Int. J. Pharm. 285:97–108.
   PubMed Web of Science ®Google Scholar
• H. Okamoto, M. Aoki, and K. Danjo. (2000). A novel apparatus for rat in vivo evaluation of dry powder formulations for pulmonary administration. J. Pharm. Sci. 89:1028–1035.
   PubMed Web of Science ®Google Scholar
• C. Seifart, U. Clostermann, U. Seifart, B. Mqller, C. Vogelmeier, P. VonWichert, and H. Fehrenbach. (2005). Cell-specific modulation of surfactant proteins by ambroxol treatment. Toxicol. Appl. Pharmacol. 203:27–35.
   PubMed Web of Science ®Google Scholar
• B. Y. Shekunov, J. C. Feeley, A. H. L. Chow, H. H. Y. Tong, and P. York. (2003). Aerosolization behaviour of micronised and supercritically-processed powders. J. Aerosol. Sci. 34:553–568.
   Web of Science ®Google Scholar
• K. Surendrakumar, G. P. Martyn, E. C. M. Hodgers, M. Jansen, and J. A. Blair. (2003). Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J. Control. Release 91:385–394.
   PubMed Web of Science ®Google Scholar
• M. P. Timsina, G. P. Martin, C. Marriott, D. Ganderton, and M. Yianneskis. (1994). Drug delivery to the respiratory tract using dry powder inhalers. Int. J. Pharm. 101:1–13.
   Web of Science ®Google Scholar
• R. K. Von. (1978). Ergebnisse einer klinischen prüfung mit ambroxol zur frage der postoperativen bronchitisbehandlung. Arzneim. Forsch. 28:934–935.
   PubMedGoogle Scholar
• X. M. Zeng, G. P. Martin, C. Marriott, and J. Pritchard. (2000). The influence of carrier morphology on drug delivery by dry powder inhalers. Int. J. Pharm. 200:93–106.
   PubMed Web of Science ®Google Scholar